Drug licensing deal brings millions in Israeli capital to Burnaby

Israel’s Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has announced that it will pay Burnaby-based Xenon Pharmaceuticals Inc. up to $376 million for a worldwide license to ...

Israel’s Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has announced that it will pay Burnaby-based Xenon Pharmaceuticals Inc. up to $376 million for a worldwide license to a pain drug that Xenon is developing.

The deal will see Teva pay Xenon $41 million up front, and then fund up to $335 million in “development, regulatory and sales-based milestones” for Xenon’s drug, XEN402. For its investment, Teva will obtain an exclusive worldwide license for the drug. Xenon will be entitled to royalties payable on sales and an option to participate in commercialization in the U.S.

Jeremy Levin, president and CEO of Teva, welcomed the deal.

“[This drug] holds the potential to address the significant unmet medical need for the many patients who suffer from chronic pain,” he said. “In addition, XEN402 has the potential for broader therapeutic use across other pain conditions.”

Simon Pimstone, president and CEO of Xenon, also expressed satisfaction with the deal.

“This partnership with Teva,” he said, “is Xenon’s seventh major pharmaceutical alliance, once again highlighting the value of Xenon’s unique genetics approach and translational R&D capabilities.”

The drug is currently in clinical development.

jwagler@biv.com

@JennyWagler_BIV

comments powered by Disqus

More from Technology

Corvus Energy’s marine power focus pays dividends

Richmond battery maker doubled its revenue between fiscal 2015 and 2016, topping BIV's list of fastest-growing companies

Read Article

BIV on Global BC August 25, 2016: Snapchat lawsuit

Read Article

Vancouver tech company targets nanomedicine niche

Precision NanoSystems develops a faster, cheaper way to produce nanoparticles

Read Article

Obamacare gives local health tech a helping hand

Increased screening in U.S. helps accelerate Vancouver company’s growth

Read Article

Making the business case for corporate data-driven decisions

Decision analytics company applies deep data to challenges faced by energy, water and government sectors around the world

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
×